ISMELIN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISMELIN is an oral small-molecule tablet approved in 1960 by Novartis for an undisclosed indication. The drug's mechanism of action and specific therapeutic area remain unspecified in available data.
LOE Approaching
Product is in advanced lifecycle stage with minimal commercial opportunity; team size and hiring activity are likely constrained.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring. Working on ISMELIN offers limited career growth, with focus likely on lifecycle management and transition planning rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on ISMELIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.